- Research Article
- 10.1016/j.elstat.2026.104276
Effect of polarity change on asymmetric cylinder-to-cylinder EHD device
- Jun 01, 2026
- Journal of Electrostatics
- I Matar + 2 more +2
Publications from 2021 to 2026
Showing 10 of 500 papers
Effect of polarity change on asymmetric cylinder-to-cylinder EHD device
SRS48 - Early fidelity and long-term drift: do we achieve preoperative alignment goals in adult spinal deformity?
Abstract Objectives To assess how often adult spinal deformity (ASD) surgery achieves preoperative sagittal alignment goals, whether corrections are durable, and the impact of planning frameworks and enabling technologies. Methods A PRISMA-guided search of MEDLINE, EMBASE, Web of Science, Cochrane Library, and Scopus through June 2025 identified studies of adults undergoing ASD surgery where alignment targets were defined by numeric thresholds (for example SVA, PI–LL, PT), algorithmic frameworks (for example Roussouly, GAP), or technology-assisted modalities (for example virtual planning, patient-specific rods, robotics, custom implants). Outcomes included plan-to-achieved fidelity, durability, complications, and PROMs. Random-effects meta-analyses were performed when data were sufficiently homogeneous (SVA < 5 cm, PI–LL ≤10°, PT ≤20°). Results Fifteen studies (2006–2025) with ∼1980 patients were included. Cohort sizes ranged 15–608; mean age was 65 years (58–72) and 68% female. Mean follow-up was 20 months (immediate to 5 years). Most patients met early postoperative targets for SVA, PI–LL, and/or PT, though durability attenuated at longer follow-up. Algorithm-driven planning—especially restoration to a Roussouly-consistent profile—was associated with fewer mechanical complications. Technology-assisted approaches improved plan-to-achieved fidelity but showed inconsistent PROM gains. Study quality varied: small single-center series were higher risk, while larger prospective cohorts showed lower but heterogeneous risk. Conclusions ASD surgery often achieves sagittal targets initially, but long-term durability is variable. Algorithmic frameworks predict fewer complications, and enabling technologies improve fidelity without consistent PROM gains. Future studies should standardize goals, assess durability beyond two years, and link alignment fidelity to patient-centered outcomes and cost.
Read morePerceived Caregiver Strain in Carers of Patients Living with Heart Failure in Collectivist Societies
Successful Treatment of Refractory Disseminated Superficial Actinic Porokeratosis With Topical Ruxolitinib
ABSTRACT This is the first documented case of disseminated superficial actinic porokeratosis (DSAP) successfully treated with topical ruxolitinib. The patient experienced near‐complete clearance after three months, suggesting that topical JAK inhibition may be an effective and well‐tolerated option for refractory porokeratosis.
Read moreComparative fermentation performance of biofilm and planktonic Saccharomyces cerevisiae under standard and high-carbon media.
IFRS adoption strategies in emerging markets and economic outcomes: evidence from a systematic literature review for the MENA region
Purpose This paper systematically reviews the literature on International Financial Reporting Standards (IFRS) adoption strategies and economic outcomes in the MENA region. It aims to explain why countries in the region exhibit divergent IFRS adoption paths, identify the main benefits and limitations of harmonisation, and explore the factors influencing adoption success. Design/methodology/approach This study employs a systematic literature review (SLR) methodology to analyse 159 academic publications, with a focus on the cultural, political, and institutional perspectives that help explain the variation in IFRS adoption strategies across MENA countries. The review also evaluates the key challenges that hinder the realisation of the anticipated benefits associated with the adoption process. Additionally, a bibliometric analysis was co-employed to uncover thematic patterns and trends within the existing literature. Findings The reviewed literature provides evidence that institutional pressures promote the IFRS adoption in the region. However, political dynamics, cultural norms, and Islamic finance often lead to partial adoption or to adoption with substantial modifications. Such adaptations tend to constrain the potential positive effects of IFRS adoption, which remain highly contingent on broader institutional reforms beyond financial reporting. Moreover, initial benefits often diminish over time due to persistent political and economic instability. Originality/value This paper offers a comprehensive, context-specific synthesis of the adoption of IFRS in the MENA region. Institutional and cultural theories are applied to explain cross-country differences in both IFRS adoption strategies and adoption outcomes. Based on the findings of the SLR, we propose a structured future research agenda focusing on regulatory adaptations, political developments, and the interaction between IFRS and Islamic finance.
Read moreBeyond Premature Atherosclerosis: Recurrent Myocardial Infarction in a Young Adult With Autoimmune Hepatitis and Factor XII Abnormality
Role of CAR-T cell therapy in pancreatic cancer: an updated narrative review of current evidence
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy projected to become the second leading cause of cancer-related deaths in the United States by 2030. Despite advances in surgery, chemotherapy, and radiotherapy, survival remains poor due to late diagnosis and treatment resistance. Immunotherapy, particularly checkpoint inhibitors, has shown limited benefit in PDAC, underscoring the need for innovative strategies. Chimeric antigen receptor T cell (CAR-T) therapy, a form of adoptive immunotherapy, has revolutionized treatment for hematologic malignancies and is now being investigated in solid tumors, including PDAC. This narrative review examines 74 articles selected from PubMed and Google Scholar, focusing on CAR-T cell therapy in pancreatic cancer. PDAC’s aggressive nature and resistance to conventional therapies highlight the urgency for novel interventions. CAR-T cells are genetically engineered to recognize tumor antigens independently of major histocompatibility complex presentation, with second-generation designs being the most utilized. Early clinical trials targeting mesothelin, human epidermal growth factor receptor 2 (HER2), and other tumor-associated antigens show promise but face challenges related to T-cell persistence, trafficking, and tumor immune evasion. Advances in CAR-T engineering continue to enhance their potential against solid tumors. While obstacles remain, CAR-T cell therapy represents a promising frontier in the management of PDAC, with ongoing research poised to improve patient outcomes.
Read moreChallenges in the timely management of severe aortic stenosis: a multicentre analysis of delayed transcatheter aortic valve implantation referrals and gender disparities
Abstract Background Gender-related disparities in diagnosis and referral to transcatheter aortic valve implantation (TAVI) remain incompletely understood. Aims This study aims to assess sex-related differences in diagnostic and therapeutic delays to TAVI and to explore sex-related disparities in management and clinical characteristics of patients with severe aortic stenosis (AS). Methods and results This multicentre, observational study included 519 patients (46.1% women) with severe symptomatic AS referred for TAVI in 2023 across three European centres. Outcomes were assessed according to VARC-3. Female-specific clinical history was systematically collected. Women were older, with higher surgical risk (STS Score: 4.5 [3.0–6.6] vs. 2.8 [1.7–4.0], P < .001) and more advanced symptoms (New York Heart Association functional Classes III and IV 87 vs. 77, P = .014). Aortic annulus dimensions and valve area were smaller in women (both P < .001). Women experienced longer delays from symptom onset to diagnosis (3 [0–9] vs. 1 [0–4] month, P < .001), with notable inter-centre variability. However, time from diagnosis to TAVI was similar (3 [1–5] vs. 2.5 [1–4.5] months, P = .220). In-hospital mortality (2.5% vs. 1.8%, P = .555), bleeding, major vascular complications, and conduction disturbances did not differ by sex. At 6 months, functional status improved significantly; mortality (4.1% vs. 5.3%, P = .685), rehospitalization, and device success (84.6% vs. 85.8%, P = .252) were comparable between sexes. Female-specific characteristics, including pregnancy, gynaecological history, and hormone therapy, were not significantly associated with clinical outcomes. Conclusions Women faced longer diagnostic delays, indicating persistent sex-based disparities in the timely recognition of severe AS. Nevertheless, clinical outcomes after TAVI were similar between sexes, supporting comparable treatment effectiveness.
Read moreBreaking Barriers: Advancements in CNS Drug Delivery for Glioblastoma.
Glioblastoma is known as the most aggressive primary brain tumor in adults, and it is still largely not curable, with a median survival of approximately 15 months when standard multimodal therapy is applied. The standard treatment nowadays is maximal safe surgical resection, associated with radiotherapy and temozolomide. Treatment effectiveness is limited not only by an impassable blood-brain barrier (BBB) to drug delivery to the brain, but also by the heterogeneity of the tumors and intrinsic or acquired drug resistance, resulting in a certain and inescapable tumor relapse. Therefore, novel drug delivery systems are being designed to overcome the BBB and improve therapeutic efficacy. These approaches include nanoparticle-mediated delivery systems, convection-enhanced intra-tumoral infusion, implantable drug-releasing devices, and noninvasive focused ultrasound technology, which induced transient disruption of the BBB. These approaches are designed to enhance local drug exposure and reduce systemic toxicity with promising preclinical and early clinical results. However, many clinical and technical challenges remain, especially the need for safety, homogeneous drug delivery, and translation of these advances into effective clinical therapies. Current glioblastoma treatment landscape and opportunities include maturing delivery systems, novel therapeutic approaches, including targeted molecular therapies and immunotherapy, as well as personalized regimens. This multidisciplinary modality may have the capacity to help not only patients with GBM but others as well through a multimodal approach of targeted drug delivery and innovative therapy in the long run to improve clinical outcomes of GBM in patients.
Read more